GLP-1 receptor agonists may reduce the risk of developing and dying from substance use disorders, a study found.The study, led by researchers at St. Louis-based WashU Medicine and published March 4 in The BMJ, analyzed data from more than 600,000 veterans with Type 2 diabetes. Compared to patients taking other diabetes medications, GLP-1 users had […]
